<DOC>
	<DOCNO>NCT01069965</DOCNO>
	<brief_summary>This safety dose find efficacy study evaluate effect BGP-15 dose range 100 mg/day 400 mg/day . Doses applied twice day 13 week add-on therapy combination metformin sulfonylurea treatment metformin alone patient Type 2 Diabetes Mellitus .</brief_summary>
	<brief_title>Safety Efficacy BGP-15 Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description>This randomize , double-blind , placebo-controlled , parallel group , multiple dose , multicenter study 5 treatment arm 1 placebo arm . Patients treat metformin SU metformin alone . Patients randomize 100,100 + 100 , 200 , 200 + 200 , 400 mg/day placebo , add-on current treatment . The study consist 2 period : - A 14-day screening period ascertain inclusion/exclusion criterion ; , - A 13-week treatment period different dose BGP-15 placebo add-on therapy metformin SU treatment metformin treatment alone .</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<criteria>Inclusion criterion Patients meet follow criterion eligible enrollment : 1 . Male female patient T2DM time diagnosis define American Diabetes Association ( ADA ) criteria ; 2 . Age 30 70 year ( inclusive ) ; 3 . HbA1c ≥7.5 % ≤12.0 % Screening , Visit 1 ; 4 . FPG ≤270 mg/dL ( 15.0 mmol/L ) ; 5 . Body mass index ( BMI ) &gt; 27 ≤40 kg/m2 ; 6 . Current treatment either metformin alone combination SU . The dose current treatment must stable least 8 week prior randomization . Patients treat metformin must optimal nearoptimal dose ( ≥1500 mg/day ± 500 mg/day range 1000 2000 mg/day ) , patient treat SU must receive least one half maximum approve SU dose ; 7 . Women may enrol three follow criterion meet : 1 . They negative serum pregnancy test Screening ; 2 . They breast feeding ; , 3 . They plan become pregnant study AND one follow three criterion meet : . They hysterectomy tubal ligation least 6 month prior sign inform consent form ; ii . They postmenopausal least 1 year ; , iii . They childbearing potential practice one follow method birth control throughout study : injectable implantable hormonal contraception intrauterine device ; two follow method birth control throughout study : oral patch contraception plus barrier contraceptive ( eg , diaphragm plus spermicide , male female condom plus spermicide , vasectomize male partner ) . Abstinence , partner 's use condom , vasectomy NOT acceptable method contraception ; 8 . Willingness sign inform consent document ; , 9 . No condition hinder participation trial , determine Investigator Sponsor . Exclusion criteria Patients meeting follow criterion ineligible enrollment : 1 . Treatment peroxisome proliferatoractivated receptor ( PPAR ) agonist ( include fibrates ) within last 3 month ; 2 . Treatment dipeptidyl peptidase 4 ( DPP4 ) inhibitor , acarbose , incretins within last 3 month ; 3 . Chronic use insulin injection within last 1 month ; 4 . Hypoglycemia require third party assistance within last 3 month ; 5 . Impaired hepatic function measure alanine aminotransferase ( ALAT ) &gt; 2X upper reference limit ; 6 . Impaired renal function measure serum creatinine &gt; 150 umol/L ( 1.7 mg/dL ) ; 7 . Decompensated heart failure ( New York Heart Association [ NYHA ] class III IV ) ; 8 . Unstable angina pectoris myocardial infarction within last 12 month ; 9 . Clinically significant ECG abnormality screen include QTc interval ( Bazett 's ) ≥450 msec AV block &gt; 1st degree ; 10 . Uncontrolled , treat untreated hypertension ( systolic blood pressure [ BP ] ≥160 mmHg and/or diastolic BP ≥100 mmHg ) ; 11 . Any condition Investigator and/or Sponsor feel would interfere trial participation evaluation result eg , drug abuse serious disease acquire immunodeficiency syndrome/human immunodeficiency syndrome ( AIDS/HIV ) antibody , Hepatitis B , Hepatitis C ; 12 . Pregnancy breastfeeding , intention become pregnant , judge use inadequate contraceptive measure ; 13 . History alcohol and/or drug dependence within last 2 year ; 14 . Receipt investigational drug medical device within 3 month prior trial ; 15 . Fasting triglyceride &gt; 700 mg/dL screening ; , 16 . Diagnosis treatment cancer within past 5 year except excision basal cell squamous cell skin lesion .</criteria>
	<gender>All</gender>
	<minimum_age>30 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>Type 2</keyword>
</DOC>